Amgen Business Segments — Provision for income taxes decreased by 62.4% to $265.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 9.1%, from $243.00M to $265.00M. This is a positive signal — lower values indicate better performance for this metric.
An increase may indicate higher pre-tax earnings or changes in tax legislation, while a decrease could signal lower profitability or the realization of tax credits and incentives.
This metric represents the total income tax expense recognized by the consolidated entity for the reporting period. It r...
Comparable to 'Income Tax Expense' or 'Provision for Income Taxes' found in the income statements of other global biotechnology and pharmaceutical firms.
amgn_segment_reportable_segment_provision_for_income_taxes| Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|
| Value | $45.00M | $48.00M | $271.00M | $243.00M | $136.00M | $705.00M | $265.00M |
| QoQ Change | — | +6.7% | +464.6% | -10.3% | -44.0% | +418.4% | -62.4% |
| YoY Change | — | — | — | +440.0% | +183.3% | +160.1% | +9.1% |